Clinical stage specialty drug organization Taris Biomedical has started patient dosing in its second Stage II review with LiRIS, for the therapy of interstitial cystitis (IC). LiRIS is intended to continually convey lidocaine to the bladder of IC patients over a lengthy period to assuage the difficult side effects related with the sickness. Sovereigns College, Canada, urology teacher and...